The endTB clinical trial is a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of five new, all-oral, shortened 9-month regimens for fluoroquinolone-susceptible multidrug-resistant tuberculosis (MDR-TB). Participants were assigned to experimental and control arms according to Bayesian outcome-adaptive randomization. The endTB randomized controlled clinical trial enrolled 754 participants across twelve sites in seven countries (Georgia, India, Kazakhstan, Lesotho, Pakistan, Peru, and South Africa). Primary outcome results are expected in the third quarter of 2023.
endTB experimental regimen 1: Bdq-Lzd-Mfx-Z
endTB experimental regimen 2: Bdq-Cfz-Lfx-Lzd-Z
endTB experimental regimen 3: Bdq-Dlm-Lfx-Lzd-Z
endTB experimental regimen 4: Cfz-Dlm-Lfx-Lzd-Z
endTB experimental regimen 5: Dlm-Cfz-Mfx-Z
For more information on this trial, visit the project website at http://www.endtb.org/clinical-trial
Registry Link